We are thrilled to announce that our company, DeepSeq.AI, Inc., a pioneering startup building the next generation of AI-driven large molecule discovery, has been awarded the 2025 Astellas Future Innovator Prize. This prestigious award, presented by Astellas Pharma U.S. Inc. in collaboration with MBC BioLabs, offers emerging life science companies a year of priority access to MBC BioLabs' state-of-the-art laboratory facilities in the San Francisco Bay Area. Additionally, DeepSeq.AI will benefit from mentorship and support from Astellas' research and development experts and business leaders.
The Astellas FutureInnovator Prize aims to accelerate early-stage drug discovery and research efforts by providing resources and guidance to promising life science companies. DeepSeq.AI was selected from over 50 applications from biotech companies for its innovative approach, therapeutic potential, and the scalability of its technological platform.
We are honored to be selected and look forward to collaborating with Astellas. This recognition reinforces our mission to transform biologics development through our unique high-throughput large-scale protein function data with explainable generative AI. Our commitment will benefit our partners by enabling the design of therapeutics optimized for conditional binding, manufacturability, efficacy, safety, and pharmacokinetics/pharmacodynamics.
About Astellas
Astellas is a global pharmaceutical company dedicated to transforming innovative science into value for patients(www.astellas.com). It focuses on therapeutic areas such as oncology, ophthalmology, urology, immunology, and women's health. Through its research and development programs, Astellas aims to pioneer new healthcare solutions for diseases with high unmet medical needs. See www.astellas.com for more information.
About MBC BioLabs
MBC BioLabs believes startups are the greatest force for positive change in the world. It offers flexible state-of-the-art lab space, facilities, access to millions of dollars in equipment and instrumentation, along with a vibrant community of like-minded individuals tackling some of the world’s biggest problems. MBC BioLabs is dedicated to helping biotech startups succeed – it enables awesome. It has helped launch and grow over 350 companies since opening in October of 2013, and together, MBC companies have initiated 176 clinical trials, introduced 71 products to market, and raised nearly $20 billion (https://mbcbiolabs.com).
